442 related articles for article (PubMed ID: 15378224)
41. Screening of drug metabolizing enzymes for fusidic acid and its interactions with isoform-selective substrates in vitro.
Chen D; Lin XX; Zhao Q; Xiao J; Peng SF; Xiao MF; Ouyang DS; Tan ZR; Wang YC; Peng JB; Zhang W; Chen Y
Xenobiotica; 2017 Sep; 47(9):778-784. PubMed ID: 27571049
[TBL] [Abstract][Full Text] [Related]
42. Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model.
Ramsden D; Perloff ES; Whitcher-Johnstone A; Ho T; Patel R; Kozminski KD; Fullenwider CL; Zhang JG
Drug Metab Dispos; 2022 Feb; 50(2):114-127. PubMed ID: 34789487
[TBL] [Abstract][Full Text] [Related]
43. Effect of Naltrexone Hydrochloride on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activity in Human Liver Microsomes.
AlRabiah H; Ahad A; Mostafa GAE; Al-Jenoobi FI
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):707-713. PubMed ID: 29744741
[TBL] [Abstract][Full Text] [Related]
44. Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes.
Misaka S; Kawabe K; Onoue S; Werba JP; Giroli M; Tamaki S; Kan T; Kimura J; Watanabe H; Yamada S
Drug Metab Pharmacokinet; 2013; 28(3):244-9. PubMed ID: 23268924
[TBL] [Abstract][Full Text] [Related]
45. Differential inhibition of rat and human hepatic cytochrome P450 by Andrographis paniculata extract and andrographolide.
Pekthong D; Martin H; Abadie C; Bonet A; Heyd B; Mantion G; Richert L
J Ethnopharmacol; 2008 Feb; 115(3):432-40. PubMed ID: 18053665
[TBL] [Abstract][Full Text] [Related]
46. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.
Taavitsainen P; Kiukaanniemi K; Pelkonen O
Eur J Clin Pharmacol; 2000 May; 56(2):135-40. PubMed ID: 10877007
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes.
Kong TY; Kim JH; Kwon SS; Cheong JC; Kim HS; In MK; Lee HS
Arch Pharm Res; 2017 Jun; 40(6):727-735. PubMed ID: 28484907
[TBL] [Abstract][Full Text] [Related]
48. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.
Turpeinen M; Hofmann U; Klein K; Mürdter T; Schwab M; Zanger UM
Drug Metab Dispos; 2009 May; 37(5):1017-24. PubMed ID: 19204080
[TBL] [Abstract][Full Text] [Related]
49. Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450.
Masek V; Anzenbacherová E; Machová M; Brabec V; Anzenbacher P
Anticancer Drugs; 2009 Jun; 20(5):305-11. PubMed ID: 19378397
[TBL] [Abstract][Full Text] [Related]
50. Inhibitory effects of the main metabolites of Apatinib on CYP450 isozymes in human and rat liver microsomes.
Pang NH; Xu RA; Chen LG; Chen Z; Hu GX; Zhang BW
Toxicol In Vitro; 2024 Mar; 95():105739. PubMed ID: 38042355
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine.
Umehara K; Shimokawa Y; Miyamoto G
Biol Pharm Bull; 2002 May; 25(5):682-5. PubMed ID: 12033517
[TBL] [Abstract][Full Text] [Related]
52. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes.
Beckmann-Knopp S; Rietbrock S; Weyhenmeyer R; Böcker RH; Beckurts KT; Lang W; Hunz M; Fuhr U
Pharmacol Toxicol; 2000 Jun; 86(6):250-6. PubMed ID: 10895987
[TBL] [Abstract][Full Text] [Related]
53. Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes.
Beckmann-Knopp S; Rietbrock S; Weyhenmeyer R; Böcker RH; Beckurts KT; Lang W; Fuhr U
Pharmacol Toxicol; 1999 Dec; 85(6):299-304. PubMed ID: 10628907
[TBL] [Abstract][Full Text] [Related]
54. Inhibitory Effects of Aschantin on Cytochrome P450 and Uridine 5'-diphospho-glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
Kwon SS; Kim JH; Jeong HU; Cho YY; Oh SR; Lee HS
Molecules; 2016 Apr; 21(5):. PubMed ID: 27128896
[TBL] [Abstract][Full Text] [Related]
55. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.
Robertson P; DeCory HH; Madan A; Parkinson A
Drug Metab Dispos; 2000 Jun; 28(6):664-71. PubMed ID: 10820139
[TBL] [Abstract][Full Text] [Related]
56. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
Nasrin S; Watson CJW; Perez-Paramo YX; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602
[TBL] [Abstract][Full Text] [Related]
57.
Lim SYM; Alshagga MA; Alshawsh MA; Ong CE; Pan Y
Drug Metab Pers Ther; 2021 Aug; 37(1):55-67. PubMed ID: 35146975
[TBL] [Abstract][Full Text] [Related]
58. Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions.
Lee KS; Kim SK
J Appl Toxicol; 2013 Feb; 33(2):100-8. PubMed ID: 21915887
[TBL] [Abstract][Full Text] [Related]
59. Searching the cytochrome p450 enzymes for the metabolism of meranzin hydrate: a prospective antidepressant originating from Chaihu-Shugan-San.
Huang X; Guo Y; Huang WH; Zhang W; Tan ZR; Peng JB; Wang YC; Hu DL; Ouyang DS; Xiao J; Wang Y; Luo M; Chen Y
PLoS One; 2014; 9(11):e113819. PubMed ID: 25427198
[TBL] [Abstract][Full Text] [Related]
60. Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay.
Tang S; Chen A; Zhou X; Zeng L; Liu M; Wang X
Toxicol Lett; 2017 Nov; 281():74-83. PubMed ID: 28941798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]